Guardant Health, Inc. Company Review & Valuation

GH
Nasdaq
Latest Price
70.10USD
Market Capitalization
7.13bUSD

About Guardant Health, Inc.

Guardant Health, Inc., a precision oncology company, provides non-invasive cancer diagnostics.

It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

The company also provides LUNAR-1 for recurrence detection in cancer survivors; and LUNAR-2 for early detection of cancer in higher risk individuals.

Guardant Health, Inc.

was incorporated in 2011 and is headquartered in Redwood City, California.

Industry
Diagnostics & Research
HQ Location
Redwood City, California

Stock Price

Price data not available for Guardant Health, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl